The central challenge the team set out to solve is deceptively simple to state and notoriously hard to achieve. Lymphatic tissue engineering, whether aimed at repairing damaged vessels, modelling disease or testing drugs, depends on having enough authentic lymphatic endothelial cells to work with. Commercial cell lines are reproducible but physiologically limited, primary cells are authentic but scarce and age quickly in culture, and induced pluripotent stem cells, while powerful, remain expensive and technically demanding. Mesenchymal stem cells from bone marrow, dermis and adipose tissue have all shown lymphangiogenic potential, but until now no differentiation protocol, according to the authors, could accurately generate lymphatic endothelial precursor cells from them.

To find the best starting material, the researchers isolated cells from three mouse tissues: the stromal vascular fraction of adipose tissue, bone marrow and dermis. The dermis was quickly ruled out, yielding only around 500,000 cells per mouse with poor viability of roughly 50 percent. Bone marrow produced abundant cells, approximately 250 million per animal with more than 90 percent viability, while the stromal vascular fraction yielded about 2 million cells with similarly high viability. Crucially, however, the adipose-derived cells proliferated roughly twice as fast as their bone marrow counterparts, reaching useful numbers in nearly half the culture time and displaying less morphological heterogeneity. Both populations passed standard mesenchymal identity tests, expressing characteristic surface markers and successfully differentiating into fat, bone and cartilage lineages under appropriate conditions.

With the cell sources validated, the team applied a differentiation protocol deliberately modelled on embryonic lymphatic development. During embryogenesis, a subset of endothelial cells in the cardinal veins is committed to the lymphatic lineage by the transcription factor PROX1, guided largely by vascular endothelial growth factor C signalling through its receptor VEGFR3. The new protocol recapitulates this molecular choreography in three stages. First, an induction phase of five days exposes the cells to VEGF-C alone. A seven-day differentiation phase then adds CCBE1, a collagen and calcium-binding protein known to potentiate VEGF-C signalling, together with angiopoietin-2. Finally, a seven-day maturation phase introduces insulin-like growth factor 2, fibroblast growth factor 2 and angiopoietin-1, factors required for proper lymphatic vessel development and maintenance.

The results were strikingly source-dependent. Nearly all adipose-derived cells, 97.4 percent on average, turned on podoplanin, a canonical lymphatic endothelial marker, with a fivefold increase in fluorescence intensity compared with their undifferentiated progenitors. Bone marrow-derived cells also increased podoplanin expression, but far more variably, reaching only 76.2 percent positivity with weaker signal intensity. Gene expression analysis reinforced the picture: adipose-derived precursor cells significantly upregulated Pdpn, Lyve1, Vegfr3, Igf2 and Vegf-c, while bone marrow-derived cells upregulated the first three but showed no changes in Igf2 or Vegf-c. Notably, neither population induced Prox1, the master transcription factor of lymphatic identity, a finding the authors discuss at length as an intriguing dissociation between marker acquisition and canonical specification.

Functionally, the adipose-derived LEPCs behaved like genuine lymphatic endothelial cells in a battery of assays. They closed scratch wounds within 48 hours, matching the migratory performance of commercial murine lymphatic endothelial controls, and their migration was significantly stimulated by VEGF-C, rivaling the response to the established chemoattractant FGF2. Their proliferation proved dependent on VEGF-C signalling, since blocking the VEGFR3 kinase with the inhibitor MAZ51 significantly suppressed growth. Transendothelial electrical resistance measurements revealed robust junctional tightness and monolayer integrity, exceeding both controls through seven days of culture. Gene expression of key lymphatic markers remained stable across three further passages after differentiation, an essential property for any cell source intended for scalable production.

Perhaps the most visually compelling evidence came from three-dimensional culture. When embedded in Matrigel hydrogels, the LEPCs rapidly assembled into web-like networks that matured into thick, tube-like structures over ten days, while the commercial lymphatic endothelial cells used as controls remained static. In planar Matrigel assays, the LEPCs likewise formed interconnected elongated structures within hours, outperforming the controls. Immunofluorescence staining confirmed that even after ten days in three-dimensional culture, the cells continued to express the canonical lymphatic markers PDPN, LYVE1 and VEGFR3 alongside F-actin, indicating that the engineered environment did not erode their acquired identity.

Transcriptomic analysis by RNA sequencing provided genome-wide confirmation of the transformation. Principal component analysis cleanly separated differentiated cells from their mesenchymal progenitors, with the first principal component alone explaining 69.2 percent of the variance. Differential expression identified 2,037 upregulated and 1,936 downregulated genes, and among the top 50 lymphatic endothelial marker genes from a published single-cell atlas, 47 were expressed in the differentiated cells, with seven, including Pdpn, Vegfr3, Lyve1, Notch1 and Cd34, significantly upregulated. Gene set enrichment analysis revealed coordinated activation of lymphangiogenesis, lymphatic vessel morphogenesis, VEGFR signalling and sprouting angiogenesis pathways, alongside a marked loss of stemness programs and a metabolic shift toward fatty acid transport and oxidation. Intriguingly, comparison against tissue-specific lymphatic endothelial subpopulations showed the closest alignment with testicular and pulmonary lymphatic endothelial cells.

The final and arguably most important test took place in living animals. The researchers labelled the LEPCs with the red fluorescent protein tdTomato and injected two hundred thousand cells beneath full-thickness skin wounds created on the backs of nude mice. Seven days after transplantation, the labelled cells were detected within and closely associated with lymphatic vessels in the surrounding tissue, their lymphatic identity confirmed by co-localization with PDPN and LYVE1. The commercial lymphatic endothelial cells used as a biological reference localized similarly, suggesting the lab-generated cells can find and integrate into the host lymphatic microenvironment after transplantation into injured tissue.

The authors are careful to frame the achievement honestly. The differentiated cells retain features of an intermediate state, most notably low Prox1 expression, and the team deliberately uses the term precursor rather than progenitor, since classical progenitor properties such as long-term self-renewal were not formally demonstrated. The protocol was also optimized in mouse cells, and its fidelity in human cells remains to be established. Nevertheless, the combination of rapid expansion, reproducible differentiation, coordinated transcriptional change and demonstrated functional competence, together with successful incorporation into a vascularized melanoma model, positions this platform as a practical new tool for lymphatic disease modelling, tissue engineering and, ultimately, therapies aimed at regenerating the body’s most overlooked vascular network.

Subject of Research: In vitro differentiation of mesenchymal stem cells into lymphatic endothelial precursor cells for lymphatic tissue engineering

Article Title: A novel approach for reliable differentiation of lymphatic endothelial precursor cells in vitro

Article References: A novel approach for reliable differentiation of lymphatic endothelial precursor cells in vitro. (n.d.). https://doi.org/10.1007/s10456-026-10097-x

Image Credits: AI Generated

DOI: 10.1007/s10456-026-10097-x

Keywords: lymphatic endothelial cells, mesenchymal stem cells, lymphangiogenesis, stromal vascular fraction, VEGF-C, tissue engineering, regenerative medicine, differentiation protocol, RNA sequencing, lymphedema, PROX1, wound healing

A joint team led by Professor Ho Min Kim of the Department of Biological Sciences at the Korea Advanced Institute of Science and Technology (KAIST) and Dr. Sangkyu Lee of the Institute for Basic Science (IBS) has determined the three-dimensional structure of the VEGF-C–VEGFR-3 complex, the central molecular interaction that triggers lymphangiogenesis, the formation of lymphatic vessels. In doing so, the team identified an unexpected layer of regulation: after the initial binding event, multiple receptor complexes gather side by side along the cell membrane, forming higher-order clusters that dramatically amplify the signal transmitted into the cell. The findings were published online on September 9 in the international journal Advanced Science under the title “Structural Basis of Lymphangiogenic Receptor VEGFR-3 Activation Mediated by Distinctive Clustering of the Ligand–Receptor Complex.”

To understand the significance of the discovery, it helps to consider how lymphangiogenic signaling has traditionally been viewed. Vascular endothelial growth factor C, or VEGF-C, is a protein that circulates through the extracellular environment and binds to VEGFR-3, a receptor embedded in the membrane of lymphatic endothelial cells. When VEGF-C engages VEGFR-3, two receptor molecules are brought together in a dimer, and this dimerization has long been considered the decisive step that switches the receptor on. Once activated, VEGFR-3 initiates intracellular signaling cascades, including the ERK pathway, that instruct the cell to proliferate, migrate, and organize into new lymphatic vessels. What happened after dimerization, however, and how the signal might be boosted beyond that initial pairing, remained poorly understood.

The KAIST and IBS researchers turned to cryogenic electron microscopy, or cryo-EM, a technique that flash-freezes protein samples at extremely low temperatures and images them with electron beams to reveal molecular structures at near-atomic resolution. Using this approach, the team visualized the VEGF-C–VEGFR-3 complex in unprecedented detail and made a striking observation: the complexes did not remain as isolated pairs. Instead, multiple VEGF-C–VEGFR-3 assemblies lined up alongside one another in the plane of the cell membrane, forming two distinct types of higher-order clusters. Cryo-EM observation showed that these assemblies organize laterally, creating an architecture that had never been described for this receptor system before.

Among the clustered arrangements, the researchers succeeded in determining the three-dimensional structure of what they term the cis-cluster, a configuration in which multiple VEGF-C–VEGFR-3 complexes are aligned side by side. The analogy the researchers draw is straightforward: two people first form a team to begin a task, and then multiple teams gather together to increase their collective strength. In molecular terms, the ligand-induced dimer represents the formation of the individual team, while the cis-cluster represents the assembly of teams into a larger, more powerful collective unit capable of generating a stronger signal inside the cell.

Crucially, the team did not stop at structural observation. They designed experiments to test whether this clustering actually matters for signaling output. By mutating VEGFR-3 at the regions where the complexes contact one another, they disrupted the ability of the complexes to form cis-clusters. The result was unambiguous: even when VEGF-C was present and able to bind the receptor, the activation of VEGFR-3 and of the downstream ERK signaling molecule was markedly reduced. The researchers also used light-based approaches to control receptor clustering directly, further confirming that the gathering of multiple complexes plays an essential role in amplifying the lymphangiogenic signal.

This identification of clustering as an amplification mechanism effectively reveals a new control point in the signaling pathway, one that Professor Kim has described as a previously unseen “hidden amplification switch” in lymphangiogenic signaling. According to Kim, the study reveals how two VEGFR-3 receptors first form a ligand-induced pair, after which multiple such complexes cluster together to further amplify the signal for lymphangiogenesis. He added that the work is expected to provide an important foundation for developing new therapeutic strategies for related diseases such as lymphedema and cancer metastasis.

The therapeutic logic cuts in two directions. In diseases such as lymphedema, where lymphatic vessel formation is insufficient, a drug that enhances VEGF-C–VEGFR-3 clustering could potentially strengthen the growth signals and encourage the regeneration of functional drainage vessels. Conversely, in cancer, where excessive lymphatic vessel growth around a tumor creates routes for metastatic spread, a molecule that blocks the contact surfaces required for cis-cluster formation could dampen signaling and starve the tumor of its lymphatic escape routes. The same structural interface that the KAIST team mapped in cryo-EM detail thus represents a potential target for both promoting and suppressing lymphangiogenesis, depending on the clinical context.

The researchers are careful to note the limits of the current work. The study did not demonstrate therapeutic effects for lymphedema or the inhibition of cancer metastasis, and considerable further research will be required before the findings can be translated into actual treatments. Structural biology of this kind provides the blueprint rather than the drug: knowing precisely how the complexes contact one another gives medicinal chemists and biologists a concrete molecular target, but designing molecules that safely modulate that interface in patients remains a long road involving drug discovery, preclinical testing, and clinical trials.

The work was a collaborative effort involving multiple contributors. Dr. Ryeongeun Cho of the KAIST InnoCORE AI-CRED Innovative Drug Research Group and Dr. Jinsook Ahn of the KAIST Department of Biological Sciences participated as co-first authors, while Professor Ho Min Kim and Dr. Sangkyu Lee served as co-corresponding authors. The research was supported by the National Research Foundation of Korea, the InnoCORE program of the Ministry of Science and ICT, the NEXUS and CELINE consortium, the KAIST Convergence Research Institute Operation Program, and the Institute for Basic Science, among others. As the structural details of the VEGF-C–VEGFR-3 cis-cluster circulate through the scientific community, the discovery stands as a vivid reminder that even well-studied signaling pathways can conceal entire layers of regulation, and that the tools of modern cryo-EM are increasingly capable of bringing those hidden mechanisms into focus.

Subject of Research: Structural basis of VEGF-C–VEGFR-3 receptor clustering in lymphangiogenic signaling

Article Title: KAIST identifies a “hidden amplification switch” in lymphangiogenic signaling, with implications for lymphedema and cancer metastasis

Article References: KAIST identifies a “hidden amplification switch” in lymphangiogenic signaling, with implications for lymphedema and cancer metastasis. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: VEGF-C, VEGFR-3, lymphangiogenesis, cryo-EM, lymphedema, cancer metastasis, receptor clustering, signal amplification, KAIST, Institute for Basic Science, Advanced Science, structural biology

The sympathetic nervous system, the body’s fight-or-flight machinery, communicates with tissues through neurotransmitters such as norepinephrine, which bind to adrenergic receptors on cell surfaces. The predominant subtype in many tissues is the beta-2 adrenoceptor, a G protein-coupled receptor that triggers cascades of intracellular messengers when activated. Epidemiological and experimental work over the past two decades has implicated this pathway in cancer progression, with studies showing that beta-blocker drugs can reduce secondary tumor formation in breast cancer patients and that sympathetic activation can induce a metastatic switch in primary breast tumors. What has been missing is a precise account of how this signaling intersects with hormone receptor biology inside tumor cells themselves.

To dissect that intersection, the team turned to two of the most widely used breast cancer cell lines in laboratory research: MCF-7 cells, which are estrogen receptor positive, and MDA-MB-231 cells, which lack the estrogen receptor. Both were grown in vitro and treated with terbutaline, a selective beta-2 adrenoceptor agonist, at two concentrations spanning a physiological range, and with propranolol, a non-selective beta-adrenergic antagonist, to test whether observed effects could be blocked. The researchers then measured a battery of outcomes: cell cycle progression as a readout of proliferation, levels of the pro-angiogenic factors VEGF-A and VEGF-C by enzyme-linked immunosorbent assay, activation of the ERK and CREB signaling proteins, nitric oxide production via the Griess assay, and expression of two cancer-associated microRNAs, miR-21 and miR-191, by quantitative PCR.

The results were strikingly divergent. In the estrogen receptor positive MCF-7 cells, terbutaline acted as an accelerant: it enhanced proliferation, boosted VEGF-C expression, raised miR-191 levels, and strengthened ERK phosphorylation, the activated form of the signaling protein. In the estrogen receptor negative MDA-MB-231 cells, the very same drug produced the opposite effect on every one of those measures, attenuating proliferation, VEGF-C output, miR-191 expression, and p-ERK signaling. In other words, a single receptor, engaged by a single ligand, pushed the two cell types in opposite biological directions, with the estrogen receptor status of the cell acting as the molecular switch that determined which way the machinery would turn.

Not everything split along receptor lines, however, and those exceptions proved equally informative. CREB phosphorylation, a second major signaling arm downstream of beta-2 adrenoceptors, was enhanced in both cell lines regardless of estrogen receptor status. VEGF-A, the canonical driver of blood vessel growth, was downregulated in both. Nitric oxide production and miR-21 expression both increased in an estrogen receptor independent fashion. These findings suggest that while the divergent outcomes in proliferation and VEGF-C regulation likely arise from selective engagement of ERK-dependent pathways shaped by estrogen receptor crosstalk, some beta-adrenergic effects operate through mechanisms that bypass the estrogen receptor entirely, underscoring the layered complexity of adrenergic signaling in breast cancer.

The microRNA data add an epigenetic dimension to the story. miR-191, which tracked precisely with the opposing proliferative responses, is a recognized player in breast cancer biology, and prior work has shown that estrogen can activate the miR-191/425 cluster in a manner that depends on estrogen receptor status. miR-21, by contrast, rose in both cell lines after terbutaline treatment, consistent with its reputation as a broadly expressed oncomir associated with multiple breast cancer subtypes. The finding that adrenergic stimulation can tune these regulatory RNAs differently depending on hormone receptor context hints that stress hormones may reshape the epigenetic landscape of tumors in a subtype-specific way.

Propranolol provided the pharmacological counterpoint. The beta-blocker significantly attenuated the terbutaline-induced effects in both cell lines, confirming that the observed changes were genuinely mediated through beta-adrenergic receptors rather than off-target actions of the agonist. Notably, the magnitude of inhibition was greater in the estrogen receptor positive cells, reinforcing the conclusion that this subtype is more exquisitely dependent on adrenergic input for the signaling responses measured. This detail carries potential clinical resonance, because it aligns with retrospective observations that beta-blocker therapy is associated with improved cancer-specific survival in breast cancer patients, and raises the possibility that patients with hormone receptor positive tumors might derive particular benefit.

The study builds on the same group’s earlier demonstration that estrogen receptor status governs how alpha-1 and alpha-2 adrenoceptors regulate cell survival and angiogenesis in breast cancer lines, and on work showing that estrogen modulates beta-2 adrenoceptor responses in immune cells through distinct intracellular pathways. Together, these findings sketch a picture in which the tumor’s hormonal identity rewires how it interprets nervous system signals. Mechanistically, the authors propose that estrogen receptor crosstalk selectively channels beta-2 adrenoceptor signaling into ERK-dependent versus CREB-dependent branches, producing the divergent proliferative and angiogenic outcomes, while parallel estrogen receptor independent routes account for the shared changes in nitric oxide, miR-21, VEGF-A, and CREB.

The implications cut in several directions. For researchers, the work is a caution against treating breast cancer as a single entity in stress-biology experiments: pooling estrogen receptor positive and negative models could average away effects that are real and opposite in each subtype. For clinicians, it adds mechanistic weight to the idea that beta-adrenergic signaling is a modifiable driver of tumor behavior, and suggests that estrogen receptor status might one day serve as a biomarker for selecting patients most likely to benefit from beta-blocker repurposing. For patients, it offers a tangible molecular account of how chronic stress physiology could influence tumor growth, at least for hormone-sensitive disease.

Important caveats remain. The findings come from cell lines in culture, where the tumor microenvironment, immune cells, vasculature, and the full neuroendocrine milieu of a living patient are absent. Concentrations, exposure durations, and the two-dimensional context of in vitro growth all shape signaling outcomes, and clinical translation will require validation in animal models and ultimately patient cohorts. Yet the core message is hard to ignore: the beta-2 adrenoceptor is not a simple on switch for cancer, but a context-dependent dial whose setting is determined by the estrogen receptor. As the authors conclude, both estrogen receptor dependent crosstalk and estrogen receptor independent adrenergic mechanisms contribute to the divergent outcomes, a duality that future therapeutic strategies targeting stress signaling in breast cancer will need to navigate with care.

Subject of Research: Estrogen receptor status determines how beta-2 adrenergic signaling regulates proliferation, angiogenic factors, and microRNAs in breast cancer cell lines

Article Title: Selective regulation of β2AR-mediated effects on cellular signaling mechanisms is governed by the estrogen receptor status of the breast cancer cell lines

Article References: Selective regulation of β2AR-mediated effects on cellular signaling mechanisms is governed by the estrogen receptor status of the breast cancer cell lines. (n.d.). https://doi.org/10.1007/s12032-026-03408-1

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03408-1

Keywords: breast cancer, beta-2 adrenoceptor, estrogen receptor, terbutaline, propranolol, ERK, CREB, VEGF-C, nitric oxide, miR-191, miR-21, cell signaling

The scale of the problem the review addresses is hard to overstate. Obesity has become a global public health crisis, and according to the World Obesity Federation’s 2025 atlas its continued rise poses significant risks for cardiovascular disease, type 2 diabetes and several cancers, while reducing life expectancy. Traditional explanations have centered on energy balance, adipose tissue expansion and chronic low-grade inflammation. What has been missing, the authors contend, is a systematic account of how the lymphatic vasculature participates in this pathology. Their review, published on 25 September 2026, sets out to map the mechanisms of interaction between lymphatic dysfunction and obesity, and to ask which direction the causality runs, a question that remains only partially answered.

Understanding the argument requires appreciating how unusual lymphatic vessels are at the structural level. Unlike blood vessels, collecting lymphatics are lined by endothelial cells joined by specialized button-like junctions that act as flaps, allowing fluid, proteins and immune cells to enter freely while preventing backflow. In the intestine, these vessels form lacteals, blind-ended capillaries in each villus that absorb dietary fat packaged into chylomicrons. The junctions between lacteal endothelial cells are remarkably plastic: work cited in the review showed that zippering these junctions shut in mice protects against diet-induced obesity by limiting fat uptake, while fibroblast subsets in the villi regulate lacteal integrity through YAP/TAZ-driven production of vascular endothelial growth factor C, or VEGF-C. In other words, the architecture of the lymphatic drainage system directly tunes how many calories the gut absorbs.

The molecular machinery governing lymphatic identity and function is equally central to the story. The transcription factor Prox1 induces the lymphatic endothelial phenotype, working with COUP-TFII to specify cell fate, while the VEGF-C/VEGFR-3 signaling axis drives lymphangiogenesis, the growth of new lymphatic vessels. VEGFR-3 signaling is required for button junction formation, and ligand-induced heterodimerization with VEGFR-2 shapes phosphorylation patterns in lymphatic endothelial cells. Other players refine the network further: semaphorin 3A, neuropilin-1 and plexin-A1 are needed for lymphatic valve formation, FOXC2 and fluid shear stress stabilize vessels after birth, and eNOS controls valve specification through beta-catenin signaling. When any of these pathways falter, the consequences ripple outward, because lymphatics do far more than drain fluid. They mediate macrophage reverse cholesterol transport, remove cholesterol from peripheral tissues via SR-BI-mediated HDL transport, and serve as gatekeepers that shape immune tolerance through molecules such as PD-L1.

Against this backdrop, the evidence that obesity damages lymphatics is strikingly consistent. Mouse studies have shown that obesity impairs lymphatic fluid transport and dendritic cell migration to lymph nodes, and that chronic high-fat feeding degrades collecting vessel function even before gross metabolic disease appears. Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and degeneration, and ApoE-deficient animals show multiple facets of lymphatic failure, including valve dysfunction on western diets. In obese animals, mesenteric lymph nodes display increased fibrosis and altered immune cellularity, and obesity-associated lymph leakage impairs the trafficking of lipids, lipophilic drugs and antigens from the intestine. Mechanistically, inflammatory cytokines appear to be key culprits: tumor necrosis factor alpha inhibits lymphatic pumping through the NF-kappaB and inducible nitric oxide synthase pathway, and inflammatory mediators disrupt endothelial barrier function. Obesity, in this framing, is an environment in which lymphatic vessels progressively choke.

Crucially, the review emphasizes that the damage is not merely collateral. Lymphatic insufficiency feeds back into metabolic disease. Mesenteric lymphatic dysfunction has been shown to promote insulin resistance, positioning the lymphatic system as a potential treatment target rather than a passive victim. Deletion of the fatty acid transporter CD36 specifically in lymphatic endothelial cells associates with visceral obesity and insulin resistance, while RAMP1 signaling deletion enhances diet-induced obesity and fat absorption through intestinal lacteals. In Prox1-haploinsufficient mice, which have inherently compromised lymphatics, restoring lymphatic function rescued the obese phenotype, one of the most direct demonstrations that lymphatic failure can cause obesity rather than simply accompany it. Lymphatic vessel insufficiency in hypercholesterolemic mice also alters lipoprotein levels and promotes atherosclerosis, extending the loop to cardiovascular disease.

The immune dimension adds another layer of complexity. Adipose tissue in obesity accumulates macrophages, and a paracrine loop between adipocytes and macrophages, driven by free fatty acids and tumor necrosis factor alpha, aggravates inflammation. Adipokines modulate this crosstalk: leptin, elevated in obesity, compromises lymphatic endothelial cell homeostasis by impairing tube formation and proliferation, and leptin-VEGF crosstalk has been implicated in excess body mass and related disorders. Adiponectin, by contrast, protects the system, modulating lymphatic vessel formation and reducing lymphedema. T lymphocytes negatively regulate lymph node lymphatic vessel formation, Th2 cytokines inhibit lymphangiogenesis, and transforming growth factor beta 1 blockade accelerates lymphatic regeneration during wound repair. Specialized pro-resolving mediators such as lipoxins interact with the lymphatic system to resolve inflammation, suggesting that the vessels are active participants in the inflammatory arc of obesity, from ignition to resolution.

What makes the review timely is its treatment implications. The authors highlight that obesity-induced lymphatic dysfunction is reversible with weight loss, and that exercise training improves obesity-related lymphatic dysfunction in animal models. A lymphoscintigraphic study found that lower extremity lymphatic function can be predicted by body mass index, linking clinical imaging to the mechanistic work. Inhibition of inflammation and inducible nitric oxide synthase improves lymphatic function in obesity, and a case report described semaglutide treatment in a patient with extreme obesity and massive lymphedema, hinting that the new generation of metabolic drugs may act partly through lymphatic pathways. Manual lymphatic drainage has been shown to alter adipokine and cytokine concentrations and markers of insulin resistance in patients with abnormal body mass index, while electroacupuncture combined with intradermal needling has been reported to influence serum markers of intestinal lymphatic function in simple obesity. Even GLP-2 has been shown to stimulate lacteal contractility and enhance chylomicron transport when the enteric nervous system is intact.

The therapeutic frontier the review sketches is correspondingly broad. Pharmacological modulation of the VEGF-C/VEGFR-3 axis could either promote lymphatic growth where vessels have failed or, in the intestinal context, be tuned to limit fat absorption, since blockade of VEGF-C and VEGF-D has been shown to modulate adipose tissue inflammation and improve metabolic parameters under high-fat diet conditions. Apelin, which inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity, represents another candidate pathway, as do receptors such as GPR182, recently identified as a lipoprotein receptor for dietary fat absorption, and the ERAD machinery protein AIDA, which selectively downregulates fat synthesis enzymes to retard intestinal fat uptake and prevent obesity. Targeting lymphatic muscle cells, valve function and junctional zippering each offer distinct intervention points, though the authors are careful to note that the directionality of causality between lymphatic dysfunction and obesity is not yet fully resolved, and that much of the evidence remains preclinical.

The broader significance of the work lies in reframing. If the lymphatic system sits at the junction of fat absorption, cholesterol trafficking, immune signaling and inflammation resolution, then it is not a peripheral curiosity in metabolic disease but a potential control node. The review, funded by the National Natural Science Foundation of China, systematically assembles the case that protecting or restoring lymphatic function could complement diet, exercise and incretin-based therapies, and that lymphatic biomarkers might one day identify patients at risk of obesity-driven metabolic complications before they manifest. It also raises an urgent clinical question: with obesity-linked lymphedema rising alongside waistlines worldwide, understanding the bidirectional crosstalk between fat and lymph may prove essential to treating both. The vessels that drain our tissues, long overlooked, may hold one of the keys to the obesity epidemic.

Subject of Research: Bidirectional relationship between lymphatic dysfunction and obesity in metabolic disease pathogenesis and therapy

Article Title: Bidirectional crosstalk between obesity and the lymphatic system: a novel pathway in obesity pathogenesis and treatment

Article References: Hao, Y., Zhang, Y., Zong, J., Wu, G., Wang, Y., Wang, J., & Wang, Y. (2026). Bidirectional crosstalk between obesity and the lymphatic system: a novel pathway in obesity pathogenesis and treatment. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02178-0

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02178-0

Keywords: obesity, lymphatic system, lymphatic dysfunction, VEGF-C, lacteals, lipid metabolism, inflammation, insulin resistance, lymphangiogenesis, adipokines, metabolic disease, lymphedema